Genmab — Juni 2019
-
The future of isatuximab https://www.oncologytube.com/video/the-future-of-isatuximab/10006630
-
Eatwell på sidste CC: We're looking for $3 billion as you know for 2019. And we expect that growth to be roughly split evenly between the 2 regions, $500 million U.S., $500 million rest of world to a total growth of $1 billion or 50%. That means with a higher U.S. starting point for the U.S., we're looking for a 42% growth U.S., 62% rest of world.
Now in terms of the growth that we anticipate for the U.S., $500 million. -
I would anticipate that may -- or frontline multiple myeloma would contribute approximately half to that. So somewhere in the $200 million to $250 million coming from the frontline indication. As Jan said, we expect approval imminently, and we expect there's going to be quite demand for that product. And we would expect the sales to pick up quite quickly.
-
-
Mens vi keder os, mere Eatwell: One other final point on that, remember that dosing for DARZALEX is that you start off with weekly dosing then go to bi-weekly and then on to your once every 4 weeks. So it does mean you do get that sort of hockey stick on the start of the sales where you get that nice, extra sales per patient certainly for the first 6 months compared to the ongoing period. So we still remain confident around our $3 billion for the year.
-
Hu..hej..hvor det går..:-D
-
oppe med 5,5%
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind